Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
10.50
-0.02 (-0.19%)
At close: Mar 9, 2026, 4:00 PM EDT
10.76
+0.26 (2.48%)
After-hours: Mar 9, 2026, 4:00 PM EDT
Valneva SE Revenue
Valneva SE had revenue of 29.41M EUR in the quarter ending September 30, 2025, a decrease of -35.82%. This brings the company's revenue in the last twelve months to 179.91M, up 13.48% year-over-year. In the year 2024, Valneva SE had annual revenue of 169.58M with 10.32% growth.
Revenue (ttm)
179.91M EUR
Revenue Growth
+13.48%
P/S Ratio
4.46
Revenue / Employee
257,017 EUR
Employees
700
Market Cap
942.29M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.72B |
| Arvinas | 262.60M |
| Maravai LifeSciences Holdings | 185.74M |
| Geron | 183.88M |
| ARS Pharmaceuticals | 142.77M |
| uniQure | 16.10M |
| Arbutus Biopharma | 14.61M |
| Aktis Oncology | 5.56M |
VALN News
- 10 hours ago - Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026 - GlobeNewsWire
- 3 days ago - VALNEVA Declaration of shares and voting rights: February 28, 2026 - GlobeNewsWire
- 7 days ago - Valneva to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 18 days ago - Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook - Wallstreet:Online
- 18 days ago - Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook - GlobeNewsWire
- 24 days ago - Valneva Provides Update on Recommendations for Use of IXCHIQ in the United Kingdom - Wallstreet:Online
- 24 days ago - Valneva Provides Update on Recommendations for Use of IXCHIQ® in the United Kingdom - GlobeNewsWire
- 4 weeks ago - VALNEVA Declaration of shares and voting rights: January 31, 2026 - GlobeNewsWire